Assessing risk of future cardiovascular events, healthcare resource utilization and costs in patients with type 2 diabetes, prior cardiovascular disease and both

被引:4
作者
Nguyen, Chi [1 ]
Luthra, Rakesh [2 ]
Kuti, Effie [2 ]
Willey, Vincent J. [1 ]
机构
[1] HealthCore Inc, Hlth Econ & Outcomes Res, Wilmington, NC USA
[2] Boehringer Ingelheim Pharmaceut Inc, Hlth Econ & Outcomes Res, Ridgefield, CT USA
关键词
Type; 2; diabetes; cardiovascular events; heart failure; risk assessment; healthcare resource utilization; healthcare costs; health economics; targeted intervention; CORONARY-HEART-DISEASE; PRIOR MYOCARDIAL-INFARCTION; ALL-CAUSE; IMPACT; MORTALITY; MELLITUS; OUTCOMES; FAILURE; HOSPITALIZATION; EPIDEMIOLOGY;
D O I
10.1080/03007995.2020.1832455
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Description of risk of cardiovascular (CV) events associated with diabetes is evolving. This US-based real-world study estimated risk of future CV events and heart failure (HF) from type 2 diabetes (T2DM) only, prior CV events only or T2DM plus prior CV events, versus controls, and evaluated healthcare resource utilization (HCRU) and costs. Methods and materials This retrospective cohort study queried claims and mortality data for 638,301 patients: T2DM only (377,205); prior CV events only (130,964); both T2DM and prior CV events (130,132); and matched (1:1) controls, during 1 January 2012-31 December 2012. Cardiovascular diagnoses/events and death were assessed individually, and as composite endpoint (myocardial infarction [MI], stroke, transient ischemic attack [TIA], peripheral artery disease [PAD]), during follow-up, ending 31 July 2018. Results Adjusting for age and gender, patients with T2DM only were 1.6, prior CV events only 2.5 and T2DM plus prior CV events 3.8 times likelier to have primary composite CV events relative to controls, p < .001. HF development was elevated across all three cohorts. Adjusted results showed inpatient admissions for T2DM only, CV events only and T2DM plus prior CV events were 1.37, 2.76 and 3.63 times greater than controls, respectively. All-cause healthcare costs were highest in the T2DM plus prior CV events cohort ($2783 per patient per month [PPPM]) followed by the prior CV events only ($1910 PPPM) and T2DM only cohorts ($1343 PPPM), and controls ($825 PPPM). Adjusted all-cause total costs were 1.48 for T2DM only, 1.49 for prior CV events only and 1.93 for T2DM plus prior CV events times higher compared to controls. Conclusion In this large and geographically broad US based cohort, CV risk for T2DM patients was elevated, as was the risk for patients with prior CV events, while patients with T2DM plus prior CV events had the highest risk of future CV events. The substantial clinical and economic burden of CV events and HF in patients with both T2DM and prior CV events suggest a need for an integrated treatment and targeted intervention across both conditions.
引用
收藏
页码:1927 / 1938
页数:12
相关论文
共 50 条
  • [31] Risk of Cardiovascular Events in Patients With Type 2 Diabetes and Metabolic Dyslipidemia Without Prevalent Atherosclerotic Cardiovascular Disease
    Rana, Jamal S.
    Liu, Jennifer Y.
    Moffet, Howard H.
    Sanchez, Robert J.
    Khan, Irfan
    Karter, Andrew J.
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (02) : 200 - 206
  • [32] Diabetes, Cardiovascular Disease, and Cardiovascular Risk in Patients with Chronic Kidney Disease
    De Lima, Jose J. G.
    Gowdak, Luis Henrique W.
    David-Neto, Elias
    Bortolotto, Luiz A.
    HIGH BLOOD PRESSURE & CARDIOVASCULAR PREVENTION, 2021, 28 (02) : 159 - 165
  • [33] Comparison of different vascular risk engines in the identification of type 2 diabetes patients with high cardiovascular risk
    Rodriguez-Poncelas, Antonio
    Coll-de-Tuero, Gabriel
    Saez, Marc
    Garrido-Martin, Jose M.
    Millaruelo-Trillo, Jose M.
    Barrot de-la-Puente, Joan
    Franch-Nadal, Josep
    BMC CARDIOVASCULAR DISORDERS, 2015, 15
  • [34] Empagliflozin Reduces the Risk of Mortality, Macro- and Microvascular Events in Patients with Type 2 Diabetes and Established Cardiovascular Disease
    Seufert, Jochen
    Galle, Jan-Christoph
    Manning, Martina
    Schmid, Volkmar
    Lehrke, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2017, 12 (04) : 294 - 306
  • [35] What is the effect of fenofibrate on cardiovascular disease events in patients with type 2 diabetes?
    Mazzone, T.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2006, 2 (07): : 366 - 367
  • [36] Lipoprotein-associated phospholipase A2 and future risk of subclinical disease and cardiovascular events in individuals with type 2 diabetes: the Cardiovascular Health Study
    Nelson, T. L.
    Kamineni, A.
    Psaty, B.
    Cushman, M.
    Jenny, N. S.
    Hokanson, J.
    Furberg, C.
    Mukamal, K. J.
    DIABETOLOGIA, 2011, 54 (02) : 329 - 333
  • [37] Complex association of serum alanine aminotransferase with the risk of future cardiovascular disease in type 2 diabetes
    Afarideh, Mohsen
    Aryan, Zahra
    Ghajar, Alireza
    Noshad, Sina
    Nakhjavani, Manouchehr
    Baber, Usman
    Mechanick, Jeffrey I.
    Esteghamati, Alireza
    ATHEROSCLEROSIS, 2016, 254 : 42 - 51
  • [38] Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes
    Guthrie, Robert
    POSTGRADUATE MEDICINE, 2016, 128 (04) : 335 - 337
  • [39] Inflammatory Bowel Disease and Risk of Global Cardiovascular Diseases and Type 2 Diabetes
    Zhu, Zhengbao
    Jia, Yiming
    Li, Fu-Rong
    Li, Yang
    Chen, Li-Hua
    Yang, Huan-Huan
    Guo, Daoxia
    Sun, Lulu
    Shi, Mengyao
    Wang, Tao
    Rohan, Thomas E.
    Qi, Qibin
    Qin, Li-Qiang
    Zhang, Yonghong
    Chen, Guo-Chong
    INFLAMMATORY BOWEL DISEASES, 2023, 30 (07) : 1130 - 1137
  • [40] Kidney function and the risk of cardiovascular disease in patients with type 2 diabetes
    Wang, Yujie
    Katzmarzyk, Peter T.
    Horswell, Ronald
    Zhao, Wenhui
    Johnson, Jolene
    Hu, Gang
    KIDNEY INTERNATIONAL, 2014, 85 (05) : 1192 - 1199